Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$21.50 USD
+0.91 (4.42%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $21.43 -0.07 (-0.33%) 4:32 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Dianthus Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
DNTH 21.50 +0.91(4.42%)
Will DNTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Other News for DNTH
Commit To Buy Dianthus Therapeutics At $12.50, Earn 26.6% Annualized Using Options
Dianthus (DNTH) Price Target Raised by Guggenheim Ahead of Key Trial
Dianthus price target raised by $8 at Guggenheim, here's why
Dianthus initiated with bullish view at William Blair, here's why
Dianthus Therapeutics (DNTH) Receives Outperform Rating by William Blair | DNTH Stock News